Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
In vivo somatostatin receptor-mediated scintigraphy has proven to be a valuable method for the visualisation of neuroendocrine tumours and their metastases. A new application is the use of radiolabelled analogues for somatostatin receptor-mediated therapy. This paper presents a review on the basic science, historical background and current knowledge of somatostatin receptor subtypes and their expression in neuroendocrine tumours. New somatostatin analogues, new chelators, "new" radionuclides and combinations thereof are also discussed. Due attention is given to limitations and future perspectives of somatostatin receptor-mediated imaging and therapy.
Breeman
W A
WA
Department of Nuclear Medicine, Erasmus Medical Centre Rotterdam, The Netherlands. breeman@nuge.azr.nl
de Jong
M
M
Kwekkeboom
D J
DJ
Valkema
R
R
Bakker
W H
WH
Kooij
P P
PP
Visser
T J
TJ
Krenning
E P
EP
D006801:Humans; D007205:Indium Radioisotopes / Q000627:therapeutic use; D008187:Lutetium; D018358:Neuroendocrine Tumors / Q000737:chemistry / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000032:analysis* / Q000145:classification; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D015021:Yttrium Radioisotopes; D013004:Somatostatin; D008187:Lutetium; D015282:Octreotide